A Phase I/II Study of CFT7455 in People with Non-Hodgkin Lymphoma or Multiple Myeloma

Share
Print

Full Title

A Phase I/II Open-label Multi-center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma or Multiple Myeloma

Purpose

The purpose of this study is to find the highest dose of the investigational drug CFT7455 that can be given safely in people with non-Hodgkin lymphoma (NHL) or multiple myeloma that has come back or continued to grow despite treatment. ¿A second purpose of this study is to assess the effectiveness of CFT7455 for treating these cancers. Some participants with multiple myeloma will receive CFT7455 in combination with dexamethasone. Both drugs are taken orally (by mouth).

CFT7455 is designed to destroy two proteins that play an important role in the growth of cancer cells. By destroying these two proteins, it may slow or stop the growth of cancer.

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have NHL or multiple myeloma that has come back or continued to grow despite previous treatment.
  • The serious side effects of prior therapies must get better before receipt of the study treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Steven Horwitz at 646-608-3725

Protocol

21-301

Phase

I/II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators